Kremer N, et al. - Authors studied 35 publications including 62 subjects receiving rituximab and 22 receiving omalizumab to quantify the safety and efficacy of rituximab vs omalizumab for the treatment of bullous pemphigoid (BP) (autoimmune blistering skin disease). They noted 85% and 84% of complete response rates for rituximab and omalizumab, respectively. Lower recurrence rate reported with rituximab (29%) as compared to omalizumab (80%). Adverse effects were recorded in 24% and 20% of cases, respectively with the mean time to recurrence, 10.2 and 3.4 months. They suggested rituximab and omalizumab with comparable safety profiles, providing the clinical benefit for subjects with BP.